Means for intravital skin whitening near blue eyes

FIELD: cosmetology.

SUBSTANCE: means is presented that is characterized by including sodium hydrogen carbonate at a temperature of 45C, hydrogen peroxide, lidocaine hydrochloride and water for injection, the components in the means are in a certain proportion in wt %. Local hyperthermic alkaline steaming, discoloration and loss of skin sensitivity with a warm bruise bleach solution and local anaesthetic easily penetrating the skin, in conditions that exclude skin piercing with an injection needle, additional blood vessel damage, interstitial bleeding, haemorrhage, hematoma formation, bruising, inflammation, abscess and sepsis.

EFFECT: non-invasive discolouration and anaesthesia of facial skin with bruises and blue eyes.

1 cl

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of immunology. Claimed is the application of a monoclonal antibody against a protein of a human Fas ligand (CD95L, or Apo1L, or FasL) or its antigen-binding fragment for manufacturing a medication for the prevention and/or treatment of skin diseases, associated with the acantholysis of keratinocytes, in particular for the prevention and/or treatment of pemphigus, where the antibody contains amino acid sequences CDR of the antibody NOK-2, F919-7-3, F918-9-4 or F919-9-18 or is produced by the hybridoma ATCC PTA-5045, ATCC PTA-5533, ATCC PTA-5534 or ATCC PTA-5535.

EFFECT: application of the antibodies by the invention or their antigen-binding fragments provides the effective blocking of mechanisms, resulting in pemphigus lesions.

7 cl, 14 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to biotechnology, namely, to peptide for stimulation of Hsp70 (heat shock protein 70) or for protection of skin against ultraviolet radiation. Peptide can be represented by peptide with general formula R1-AA1-AA2-AA3-AA4-R2, its stereoisomers, their mixture and/or their cosmetically or pharmaceutically acceptable salt. AA1 represents -His-; AA2 is selected from the group, consisting of -His-, -Leu- and -Pro-; AA3 represents -Leu-; AA4 is selected from the group, consisting of -Arg- and -Asn-.

EFFECT: claimed invention makes it possible to obtain novel peptide, which is effective for stimulation of Hsp70 synthesis or for protection of skin against ultraviolet radiation.

17 cl, 1 tbl, 16 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyrimidine compounds of formula (I) , in which A is selected from NH, O and S; R1 is selected from (C1-C6)-alkyl, (C3-C7)-cycloalkyl-CtH2t and Het-CtH2t-, where t is selected from 0, 1, 2 and 3; R2 is selected from phenyl and residue of aromatic 5-member - 6-member monocyclic heterocycle, which includes 1, 2 similar or different ring heteroatoms, selected from N, O and S, in which one of ring nitrogen atoms can carry atom of hydrogen or substituent R21, and in which phenyl and aromatic heterocycle residue are optionally substituted in one or more ring carbon atoms with one or more similar or different substituent R22; R3 is selected from (C1-C6)-alkyl, or R3 represents residue of saturated or unsaturated 3-member - 10-member, monocyclic or bicyclic ring, which includes 0, 1, 2 or 3 similar or different ring nitrogen atoms can carry hydrogen atom or (C1-C4)-alkyl substituent and one or two ring sulphur atoms can carry one or two oxo groups, and in which ring residue is optionally substituted in one or more ring carbon atoms with similar or different substituents R31, on condition that R3 cannot be (C1-C6)-alkyl, if A represents S; other values of radicals are given in i.1 of formula.

EFFECT: compounds of formula (I) are suitable for wound healing.

16 cl, 2 tbl, 9 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to field of immunology. Claimed is application of monoclonal antibody against human Fas ligand protein (CD95L, or Apo1L, or FasL) or its antigen-binding fragment for manufacturing medication for prevention and/or treatment of skin diseases, associated with acantholysis of keratinocytes, in particular for prevention and/or treatment of pemphigus, where antibody contains amino acid sequences CDR of 3E1 antibody or is produced by hybridoma ATCC PTA-4017.

EFFECT: application of antibody in accordance with invention or its antigen-binding fragment provides more effective prevention of desmoglein (dsg3) cleavage in comparison with application of other antibodies.

11 cl, 16 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents a suspension for treating psoriasis, containing calcipotriol monohydrate in the form of nanocrystals having the particle size distribution within the range of 200-600 nm; the particles are dispersed in an aqueous phase containing a non-ionic polymer surfactant specified in a group consisting of a surfactant in the form of poloxamers or polysorbates, in the amount of 0.01-5 wt % calculated using a suspension for preventing development of aggregation and/or calcipotriol monohydrate nanocrystal growth; the calcipotriol monohydrate nanocrystals are produced in the suspension by processing the suspension by a method involving the stages of reduction in crystalline calcipotriol monohydrate particle size in an aqueous phase to form microparticles having the particle size distribution within the approximate range of 5-20 mcm and the average approximate particle size of 10 mcm; the suspension is exposed to three high-pressure homogenisation cycles for 7-15 minutes each; in the first, second and third cycles, the pressure makes 300-800 bars, 800-1,200 bars and 1,200-1,700 bars respectively.

EFFECT: invention provides creating the local composition containing calcipotriol as an active agent, however being free from propylene glycol as a solvent.

34 cl, 8 ex, 5 tbl, 9 dwg

FIELD: medicine.

SUBSTANCE: to improve functional-aesthetic results of the plastic surgery of post-traumatic eyelid deformations, starting from 7-8 day from the moment of carrying out blepharoplasty of the post-traumatic cicatrical eyelid deformation, immediately after the removal of operational sutures, on the operated zone of the eyelid performed is a procedure of magnetic-photophoresis of a medical solution, made from 3000 ME of longidaze, 3 ml 25% solution of dimethylsulphoxide and 1 ml 0.25% solution of derinate, with 2 ml of the prepared solution being applied on an autodermal transplant and healthy skin surrounding it, with up to 1 cm indent from the wound edge, after 3-5 minutes a gauze pad, soaked with 2 ml of the remaining prepared solution, is applied on the processed surface of skin with the further 10 minute impact by a contact method by a travelling pulsed magnetic field of the apparatus "AMO-ATOS" with the frequency of pulse consecution of 5-10 Hz. Then, after the pad is removed, without the time interval, borders of the autodermal transplant and healthy skin closing are processed by infrared laser irradiation of a range of 0.89 mcm of the apparatus UZOR-2K with the frequency of the pulse repetition rate of 1500 Hz, in accordance with a contact labile method, 1 minute on each field, with carrying out 1 procedure daily for 10 days.

EFFECT: improvement of the quality of skin transplant engraftment, absence of secondary eyelid deformations, and reduction of the post-operational treatment duration.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetology, namely represents a composition containing minoxidil and/or minoxidil sulphate combined with additives containing at least one antioxidant, at least one organic acid and selected fatty acids mixture. Besides, the invention refers to using the compounds for hair growth enhancement/recovery and/or hair loss prevention in mammals, particularly in a human.

EFFECT: using the invention provides faster anagen phase in mammalian hair growth and/or enhanced terminal hair above the skin surface by local application the declared compositions.

19 cl, 9 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely to dermatology, and can be used for preventing and/or treating skin itching. It involves using L-serine as a therapeutic agent, a pharmaceutical composition containing L-serine, as well as a dermato-cosmetic composition containing L-serine as a single active agent, Avene Thermal Spring Water, glycerine and a cosmetically acceptable carrier. The L-serine concentration in the composition makes from 0.01 wt % to 10 wt % in relation to the total weight of the composition. More preferentially, the concentration makes 0.5 wt % to 3 wt % in relation to the total weight of the composition.

EFFECT: group of inventions provides the effectiveness of application.

8 cl, 2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine, namely to dermatology and mycology, and can be applied in the treatment of skin and its appendages. A pharmaceutical composition for external application contains nanoparticles for the laser thermotherapy of infectious affections of the skin and its appendages. The nanoparticles are characterised by, at least, one localised surface Plasmon resonance in the range of a wavelength from 400 to 1100 nm. The nanoparticles are dispersed in a physiologically acceptable carrier, which is characterised by the absence of the absorption or weak absorption and/or weak dispersion of light radiation in the said range of wavelengths and possessing biocidal properties. The pharmaceutical composition is applied on an affected area and irradiated by laser radiation with a wavelength close to the wavelength of the localised surface Plasmon resonance of the nanoparticles, contained in the composition, or equal to it. The irradiation is continued until the desirable temperature of heating of the said area is achieved.

EFFECT: group of inventions ensures an increased treatment efficiency, reduction of a risk of development of side effects, reduction of the number of recurrences due to the application of the pharmaceutical composition, capable of absorbing energy of the light radiation and transforming it into heat energy with the achievement of the specified temperature with laser irradiation at the specified wavelength with the lower intensity of laser radiation and possessing biocidal properties.

63 cl, 3 dwg, 1 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry and represents a pharmaceutical composition for the external application for the treatment of skin diseases in the form of a cream, which includes as an active substance methylprednisolone aceponate in a therapeutically effective amount and a lipophilic base, characterised by the fact that as the lipophilic base it contains petrolatum, liquid paraffin and oil of castor oil plant seeds and additionally white bee wax, with the components of the composition being in a specified ratio in g/100 g of the composition.

EFFECT: invention provides the creation of the stable composition, improved pharmacological properties and absence of an irritating effect.

1 tbl

FIELD: medicine.

SUBSTANCE: at the first stage, after removing supra- and sub-gingival dental calculus and granulations, cleaning the teeth professionally, rinsing gingival pockets by stream infusions of 1.5% hydrogen peroxide in a cannula delivered through the gingival pockets around the teeth, brought under root furcation if observing the exposed furcation of premolars and molars; the preparation "Calsept" is administered within the frontal teeth for 5-7 days daily into the gingival pockets bringing the cannula similarly around the teeth, whereas the preparation "Calsept-Iodo" is administered within the distal teeth; the dentist recommends that the patient does not eat for 2 hours thereafter. The second stage involves administering a preparation containing bifidus bacteria, e.g. Normoflorin-B or Bifidumbacterin by instillations in a cannula delivered through the gingival pockets around the teeth, brought under the furcation if observing the exposed furcation of premolars and molars; gingival mucous membranes are laid with cotton drains with the preparation for 2 hours daily for 5-10 days.

EFFECT: using the method provides increasing the therapeutic effect ensured by the antibacterial effect, odontotropic and anaesthetic action, bone tissue recovery, action of the therapeutic preparation in difficult-to-access anatomic formations.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: wound surface is treated with 3.0-1.5% hydrogen peroxide; then keeping the wound wet, Ichthyosin dressing prepared by streptocide powder 0.5-2.5g and Ichthyol ointment 5.0-10.0g dissolved in castor oil 94.5-87.5ml is applied. The agent is applied once a day; the therapeutic course makes 16 days. That is combined with performing an integrated treatment.

EFFECT: invention provides both the antibacterial and anti-infectious, and local anti-inflammatory, local anaesthetic, wound-healing effects, improves the blood supply, stimulates the epidermis regeneration, intensifies the keratosis processes that enables accelerating the wound cleansing from the purulonecrosis process, and a length of preparation for aurografting.

1 tbl, 2 ex

Bruise bleacher // 2539380

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, and represents a bruise bleacher in the form of an aqueous solution for intradermal or subcutaneous injections containing sodium bicarbonate, hydrogen peroxide, disodium edetate, and water for injection, wherein the components of the solution are taken in a certain ratio, wt %.

EFFECT: invention provides extending the range of bruise bleachers.

FIELD: medicine.

SUBSTANCE: invention can be applicable for treating patients suffering haemorrhagic shock. Namely, the invention refers to a hyperoxygenated agent for venous oxygen saturation, which represents an aqueous solution containing sodium chloride 0.85%, sodium hydroxycarbonate 0.10% and hydrogen peroxide 0.05-0.29%.

EFFECT: higher safety and effectiveness by blood oxygen saturation, stable osmotic activity, higher alkalinity and buffer capacity.

FIELD: medicine.

SUBSTANCE: patients keep a diet with reducing an amount of liquid taken up to 1.5l a day that is compensated by the intravenous administration of solutions an amount and composition of which depends on a degree of water-electrolyte disturbances. Additionally, after bandage removal, the wound and edges of the fistulous passage is 5% potassium permanganate, which is then washed with 3% hydrogen peroxide. A mouth of the fistula and the wound edges are dried. That is followed by an aeration of the mouth of the fistula with a cooled plasma flow of nitrogen monoxide at a depth of 0.5cm in the therapeutic mode of 2000 mg/m3 and exposition of 1.5min. The mouth of the fistula and the wound edges are treated with a plasma flow of nitrogen monoxide in the concentration within the contact area with the wound surface of 1500 mg/m3 and time of exposure of 20 seconds per each 1 cm2 of the surface. The mouth of the fistula and the wound edges are dried. The mouth is packed with the gauze swab. The fistulous wound is exposed to EHF waves with the pure noise spectrum and the provided integral power on the wound surface of 1.5 mcWt along the perimeter of the mouth at 15mm from the fistulous passage for 30 minutes. The swab is removed. The mouth and the surrounding skin is treated with zinc paste and covered with gauze swabs. The further bandages are performed in the similar way as the bandage wets with the intestinal contents, but no more than 2 times a day and at least once every 3 days.

EFFECT: safe and effective conservative treatment of the intestinal fistulas at any phase of the wound process that enables avoiding risks of surgical intervention and general anaesthesia by rapid reduction of skin maceration and perifocal inflammation surrounding the mouth and prevents them, stimulates the growths of granulocyte tissue and epithelisation of the fistuous wound.

FIELD: medicine.

SUBSTANCE: biologically active additive Laviocard+ is prescribed orally 1 capsule 2 times a day with food for 21 days. That is combined with daily wound irrigations with neutral analyte of anhydrohexitol nucleic acid with leaving a sterile gauze bandage impregnated with neutral analyte of anhydrohexitol nucleic acid in the wound until it is clean. That is followed by daily bandaging with Lavitol cosmetic dihydroquercetin powder applied on the wound surface 1-2 mm thick until the wound is healed.

EFFECT: reduced length of wound healing by stimulating the regeneration processes in tissues.

1 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention concerns a stabilised antimicrobial gel compound containing hydrogen peroxide (H2O2) and other additives. As the additives, the compound contains the thickener cellulose ester, the stabiliser dipotassium hydrogenphosphate (K2HPO4) and disodium salt ethylenediamine-N,N,N1,N1-tetraacetic acid (Na2EDTA), glycerol and water in certain proportions.

EFFECT: preparing the antimicrobial compound with stabilised hydrogen peroxide with no toxic components used, applicable as skin antiseptics, eg for hand cleaning.

2 cl, 21 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: 10 daily procedures of ozone therapy are performed. The 1st and 2nd procedures involve saturating 0.9% sodium chloride 200 ml with ozone-oxygen gas mixture in the concentration of 10 mg/l for 2 minutes and administering intravenously for 20 minutes. For the 3rd and 4th procedures, 0.9% sodium chloride 200 ml is saturated with ozone-oxygen gas mixture in the concentration of 15 mg/l for 2 minutes and administered intravenously for 20 minutes. According to the 5th, 6th, 7th, 8th, 9th and 10th procedures, 0.9% sodium chloride 200 ml is saturated with ozone-oxygen gas mixture in the concentration of 20 mg/l for 2 minutes and administered intravenously for 20 minutes. Ozone therapy is further followed 1 hour later with 10 sessions of gravity therapy, which involves the four-staged exposure of a patient to centrifugal forces in the direction from head to lower extremities. At the first stage, a centrifuge rotation speed is 32 rpm with a length of the session being 10 min - 1 session. At the second stage, the centrifuge rotation speed is 34 rpm with a length of the session being 10 min - 2 sessions. At the third stage, the centrifuge rotation speed is 36 rpm with a length of the session being 15 min - 3 sessions. At the fourth stage, the centrifuge rotation speed is 36 rpm with a length of the session being 20 min - 4 sessions.

EFFECT: invention enables achieving collateral blood flow stimulation, atherosclerosis regression, a lower degree of ischemia in patients with obliterating lower extremity atherosclerotic vascular disease by a combination of methods of gravity and ozone therapies.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely therapy, and concerns treating the patients suffering the multiple organ pathology using ozone therapy. That is ensured by the intravenous introducing of ozonised saline 200 ml at 10-15 ml/min for 15-20 min into the patient with the inactive disease. The adult patients require the ozone therapy to be performed daily in the form of 6 sessions with the saline ozone concentration of 0.15 mg/l, while the ozone therapy in the elderly and senile patients is performed every second day in the form of 10 sessions with the saline ozone concentration of 0.10 mg/l.

EFFECT: method provides the effective and safe treatment of the multiple organ pathology ensured by the low saline ozone concentration, providing the absence of hemolysis, and by choosing the mode and ozone concentration optimal for the various age groups.

2 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, pharmacology, to methods and PTEN phosphatase inhibitor compositions for ovarian follicle and oocyte development in vitro. Using the PTEN phosphatase inhibitors, such as complexes of oxovanadate and peroxovanadate: bisperoxo (bipyridine) oxovanadate, bisperoxo (1,10-phenanthroline) oxovanadate, bisperoxo (picolinato) oxovanadate, bisperoxo (5-hydroxypyridine-2-carboxyl) oxovanadate, di- (picolinat) oxovanadate, di-(3-hydroxypicolinat) oxovanadate, bisperoxo (phenylbiguanide) oxovanadate, di-(phenylbiguanide) oxovanadate and bisperoxo (isoquinoline carboxylic acid) oxovanadate, provide the development and activation in vitro of oocytes and follicles, such as primordial, intermediate and primary ovarian follicles.

EFFECT: invention provides the development and activation in vitro of oocytes and follicles, such as primordial, intermediate and primary ovarian follicles.

14 cl, 3 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely to a formulation of a cough medical composition. The formulation of the cough medical composition contains an active substance presented by thermopsis herb powder or a dry extract of thermopsis and sodium hydrocarbonate, as well as an excipient, a granulating agent and a lubricant taken in certain relations (versions).

EFFECT: composition of the cough medical composition possesses improved pharmaceutical (appearance, taste) and technological characteristics (hardness, disintegration).

11 cl, 7 ex

Up!